Clinical Trial Update: Multicenter, Phase II Clinical Study of Sacituzumab Tirumotecan (Sac-TMT) in Combination With KL-A167 for Neoadjuvant Treatment of Triple-Negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase II multicenter trial evaluating Sacituzumab Tirumotecan in combination with KL-A167 as neoadjuvant therapy for triple-negative breast cancer is currently …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• KL-A167
• Sacituzumab Tirumotecan (Sac-TMT)

Snippet

Sponsor: Shanghai Jiao Tong University School of Medicine | Conditions: Breast Cancer | Phase 2 | Status: RECRUITING